companiesCompany

Foresite Capital

A San Francisco investment firm that funds healthcare companies at every stage with a data-science approach. Its cancer investments include CG Oncology, ALX Oncology, Kura Oncology and the blood-test company Delfi Diagnostics.

Foresite Capital was founded in 2011 by Jim Tananbaum and is headquartered in San Francisco (Wikipedia). It describes itself as 'a multi-stage healthcare and life sciences investment firm' that uses 'a data science-driven approach to invest in companies that leverage biology and big data to transform healthcare', and also incubates companies through Foresite Labs. Its portfolio page lists current and alumni holdings including ALX Oncology, Arcus Biosciences, Aura Biosciences, CG Oncology, Cullinan Therapeutics, Corvus Pharmaceuticals, Delfi Diagnostics (early cancer detection), Karyopharm, Kura Oncology and Lyell Immunopharma; the homepage quotes Theseus Pharmaceuticals on 'our mission to outsmart cancer resistance' and 10x Genomics' chief executive.

Headquarters

San Francisco, CA, US

Type

investor

Website

www.foresitecapital.com/

Founded

2011

Portfolio

5top

Portfolio in OnCo (5)

Filter the startups table

Company	Stage	Type	Cancers	Latest round
Mythic Therapeutics Waltham, MA, US	Wound down	biotech	Non-small-cell lung cancer	Series B 2021, $103M
Nested Therapeutics Cambridge, MA, US	Startup	biotech		Series A 2022, $90M
Obsidian Therapeutics Cambridge, MA, US	Public	cell therapy	Melanoma Non-small-cell lung cancer	Crossover 2026, $350M
Tango Therapeutics Boston, MA, US	Public	biotech	Pancreatic ductal adenocarcinoma Non-small-cell lung cancer Glioma & glioblastoma	IPO 2021, $353M
Thyme Care Nashville, TN, US	Growth stage	cro services		Series E 2026, $125M